Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy.

D Begley1, S Mohiddin, L Fananapazir

  • 1Inherited Heart Diseases Section, Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

Pacing and Clinical Electrophysiology : PACE
|January 31, 2002
PubMed
Summary

Dual chamber (DDD) pacemaker therapy significantly improved symptoms and reduced pressure gradients in patients with mid-cavity obstructive hypertrophic cardiomyopathy (HCM). This therapy offers a viable alternative for patients unsuitable for traditional cardiac surgery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of modified-release opioid use on clinical outcomes following total hip and knee arthroplasty: a propensity score-matched cohort study.

Anaesthesia·2023
Same author

Impact of an Australian/New Zealand organisational position statement on extended-release opioid prescribing among surgical inpatients: a dual centre before-and-after study.

Anaesthesia·2021
Same author

Case fatality rates for South Asian and Caucasian patients show no difference 2.5 years after percutaneous coronary intervention.

Heart (British Cardiac Society)·2011
Same author

Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6).

Journal of medical genetics·2004
Same author

Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis.

European journal of human genetics : EJHG·2002
Same author

Identification of a gene responsible for familial Wolff-Parkinson-White syndrome.

The New England journal of medicine·2001

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Medical Devices

Background:

  • Intracavitary left ventricular (LV) obstruction is a key factor in hypertrophic cardiomyopathy (HCM) outcomes.
  • Mid-cavity obstructive HCM, sometimes with LV aneurysm, presents challenges for standard surgical intervention.
  • This specific obstruction pattern affects a minority of HCM patients and may indicate a poorer prognosis.

Purpose of the Study:

  • To evaluate the long-term efficacy of dual chamber (DDD) pacemakers in managing mid-cavity obstructive HCM.
  • To assess the impact of DDD pacing on symptoms, functional class, and hemodynamic parameters in this patient subset.

Main Methods:

  • A study involving 14 patients with mid-cavity obstructive HCM (mean age 34 years).
  • Patients received DDD pacemakers and were assessed via cardiac catheterization before and after therapy (6 months to 1 year follow-up).

Related Experiment Videos

  • Drug therapy was discontinued during the evaluation period.

    • Main Results:

    • All patients experienced symptomatic improvement, with a significant reduction in NYHA functional class (from 2.8 to 1.9, P < 0.0005).
    • Intracavitary LV pressure gradients decreased significantly (from 84 to 43 mmHg, P < 0.0005).
    • A significant reduction in apical LV systolic pressure and a trend towards increased exercise tolerance were observed.

    Conclusions:

    • Chronic DDD pacing provides substantial symptomatic and hemodynamic benefits for patients with mid-cavity obstructive HCM.
    • This therapy is a valuable option for patients with this specific HCM subtype, where surgical options are less defined.